Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

NCT00391066 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
627
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Biogen